The Guidant Bio FHAB mechanism of action
Our modular FHAB construct utilizes a validated, uniquely configured, albumin-binding approach to deliver selected payloads directly to the tumor microenvironment for enhanced penetration, retention and local activation.
Technology founded by industry expertise
Guidant Bio combines deep expertise in immune biology with integrated capabilities in drug discovery and product development. Our Fully Human Albumin-Binding (FHAB) construct is the foundation of a modular, Navigated Delivery™ platform for biologic therapeutics. Human serum albumin, the most abundant protein in plasma, undergoes receptor-mediated recycling via the neonatal Fc receptor (FcRn) and preferentially accumulates in inflamed tissues, including tumors, through active transport processes.
Guidant Bio FHAB-based therapeutics are built on engineered protein constructs that attach at a uniquely chosen site on native albumin, preserving FcRn engagement and albumin trafficking pathways. As a result, these therapies leverage the endogenous albumin transport biology to achieve prolonged systemic half-life and concentrated retention in the tumor microenvironment. By coupling therapeutic payloads to albumin, the FHAB platform enhances tissue exposure at sites of disease and improves the overall therapeutic index through reduced off-target distribution and systemic toxicity.
